{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T01:27:40Z","timestamp":1777253260735,"version":"3.51.4"},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,9,15]]},"DOI":"10.2169\/internalmedicine.9879-17","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T22:30:36Z","timestamp":1526596236000},"page":"2753-2757","source":"Crossref","is-referenced-by-count":21,"title":["The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib"],"prefix":"10.2169","volume":"57","author":[{"given":"Yoshinori","family":"Mori","sequence":"first","affiliation":[{"name":"Division of Chemotherapy, Nagoya City University Hospital, Japan"},{"name":"Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Japan"},{"name":"Division of Chemotherapy, Nagoya City West Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Division of Chemotherapy, Nagoya City University Hospital, Japan"},{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kanamori","sequence":"additional","affiliation":[{"name":"Division of Chemotherapy, Nagoya City University Hospital, Japan"},{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Joh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Takemoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nagoya City University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nagoya City University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nagoya City University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Division of Chemotherapy, Nagoya City University Hospital, Japan"},{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 77: 163-171, 2011.","DOI":"10.1016\/j.critrevonc.2010.02.012"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379: 1879-1886, 2012.","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348: 694-701, 2003.","DOI":"10.1056\/NEJMoa020890"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33: 3036-3046, 2015.","DOI":"10.1200\/JCO.2014.59.5256"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Biswas B, Bakhshi S. Management of Ewing sarcoma family of tumors: current scenario and unmet need. World J Orthop 7: 527-538, 2016.","DOI":"10.5312\/wjo.v7.i9.527"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ikeda AK, Judelson DR, Federman N, et al. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol Cancer Ther 9: 653-660, 2010.","DOI":"10.1158\/1535-7163.MCT-09-0812"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ackermann M, Morse BA, Delventhal V, Carvajal IM, Konerding MA. Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing's sarcoma A673-xenograft growth and normalize tumor vascular architecture. Angiogenesis 15: 685-695, 2012.","DOI":"10.1007\/s10456-012-9294-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hamdan R, Zhou Z, Kleinerman ES. Blocking SDF-1alpha\/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors. Mol Cancer Ther 13: 483-491, 2014.","DOI":"10.1158\/1535-7163.MCT-13-0447"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yamamoto Y, Nozawa M, Shimizu N, Minami T, Yoshimura K, Uemura H. Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum. Int J Urol 21: 1183-1184, 2014.","DOI":"10.1111\/iju.12546"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Alcindor T. Response of refractory Ewing sarcoma to pazopanib. Acta Oncol 54: 1063-1064, 2015.","DOI":"10.3109\/0284186X.2014.971938"},{"key":"11","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.4081\/rt.2015.5992","volume":"7","author":"S Attia","year":"2015","unstructured":"11. Attia S, Okuno SH, Robinson SI, et al. Clinical activity of pazopanib in metastatic extraosseous ewing sarcoma. Rare Tumors 7: 5992, 2015.","journal-title":"Rare Tumors","ISSN":"https:\/\/id.crossref.org\/issn\/2036-3605","issn-type":"print"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Bancalari E, de Alava E, Tardio JC. Primary vaginal Ewing sarcoma: case report and review of the literature. Int J Surg Pathol 20: 305-310, 2012.","DOI":"10.1177\/1066896911424898"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/18\/57_9879-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T05:15:58Z","timestamp":1537074958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/18\/57_9879-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,15]]},"references-count":12,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9879-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,15]]}}}